AcelRx Pharmaceuticals (ACRX) shares rose strongly in trading today. The company received initial coverage from Credit Suisse, with an outperform rating and $7 price target. ACRX recently received FDA approval in late 2018 for its powerful opioid DSUVIA. The company insists that it will tightly regulate the distribution and dosage so as to avoid patients becoming addicted to the drug. Here’s a recap.
Jeff Bezos just sold 15 million shares of Amazon (AMZN) and the headlines are everywhere. Scott Bauer joined Business First AM to cut through the noise and give his honest take on whether this move should change anything for investors.
Read Article
AMD is under pressure today and Scott Bauer sees an opportunity in the selloff. He joined Schwab Network to walk through the trade he is putting on and share why he is feeling cautious about the broader market right here.
Read Article
Charlie Moon joined Schwab Network to break down a non-directional options trade on Palantir heading into earnings and share his big picture read on what the market could be setting up for in August.
Read Article
Scott Bauer joined the IBKR Podcast this week to break down what moved markets last week and what investors need to watch heading into the next stretch of earnings season. From lagging inflation data to big tech CapEx concerns, Scott did not hold back.
Read Article
The Dow rose more than 1% to a record closing high on Thursday ahead of the long holiday weekend as a softer-than-expected U.S. jobs report eased worries about interest rate hikes, while another sharp drop in chipmaker stocks weighed on the Nasdaq. The second half of 2026 kicked off this week much the same as […]
Read Article
A renewed sell-off in technology stocks grabbed headlines this week. The Nasdaq index fell 4.5%, closing lower 5 days in a row, led by a large 5.5% decline in the so-called Magnificent 7 mega cap names. Meanwhile, the post IPO exuberance around SpaceX appears to be fading, with shares now down 25% from their peak. […]
Read ArticleWe choose to let our members and students speak for themselves. We do not actively solicit testimonials, no compensation has been paid for any testimonial, and testimonials are not necessarily representative of the experience of all students. All monetary claims made in testimonials that you see depicted in our marketing material have been verified by Prosper Trading Academy and attested to by the members that have given them. Verified testimonials encompass “experience” reviews that highlight the personal experiences of working with our team and “performance” testimonials where we verify trading success of students who have enrolled in our programs.Given the broad reach of the internet, testimonials and reviews of our programs that we have not been able to verify can be found on various websites across the internet which are beyond our editorial control. While we do very much enjoy hearing positive things from our students and it is critical to our mission that everyone is satisfied with their journey with Prosper, we encourage you to take both verified and unverified testimonials for what they are.